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Abstract
Background: The Carpentier-Edwards Perimount Magna mitral valve bioprosthesis (Edwards Lifesciences, Irvine, CA) is
a low-profile version of the earlier Perimount valve that uses the ThermaFix process for enhanced calcium removal. The
Magna valve has been in use since 2008, yet no publication, until now, has verified its intermediate-term safety and
efficacy.
Methods: From 2008 through 2011 (our 4-year study period), 70 Magna valves were implanted in the mitral position at
a single institution (the Cleveland Clinic). Echocardiograms were prospectively interpreted. For this study, we reviewed
patients’ charts; endpoints included hemodynamic measurements, in-hospital morbidity and mortality, valve-related
events, resource utilization, and 5-year survival rates.
Results: The mean patient age was 68 years; 43 % of the patients had New York Heart Association (NYHA) class III
or IV disease, and 51.4 % had moderately severe, or worse, mitral regurgitation (MR). For 43 % of the patients, the
Magna valve implantation was a reoperation. For 83 %, the Magna valve implantation also included a
concomitant cardiac procedure. The median survival rate was 4.7 years and 90 % of patients were free from
significant structural valve degeneration at 5 years. Preoperative atrial fibrillation, ischemic MR, intraaortic balloon
pump placement, cardiogenic shock, cardiac arrest, and renal failure were associated with increased mortality.
Right ventricular systolic pressure decreased from 50 mmHg preoperatively to 40 mmHg postoperatively,
according to our matched-pair analysis (P = 0.003). Per their final echocardiogram during our study period, 98 %
of surviving patients had trivial or no MR, one patient had mild MR, and one patient had severe MR.
Conclusions: Our 5-year experience indicates that the Magna valve offers excellent intermediate-term durability
and substantial echocardiographic improvement; its low-profile design make it ideal for reoperations and for
concomitant cardiac procedures, including valve replacement.
Background
Each year, more than 20,000 mitral valve operations are
reported to the Society of Thoracic Surgeons database [1].
Despite the increased emphasis on valve repair, at least
30 % of patients with mitral valve disease still undergo
valve replacement [2–4]. Reasons include extensive co-
morbidities, previous valve operations, complex jets, and
mitral stenosis [3]. The ideal replacement valve would be
durable, would not require anticoagulation, and would be
small enough to avoid distortion of the mitral annulus
while preserving left ventricular geometry.
A mitral valve bioprosthesis avoids anticoagulation,
but is associated with a higher reoperation rate than a
mechanical valve. For patients older than 70 years and
for patients with a contraindication to anticoagulation,
a mitral valve bioprosthesis is the preferred replace-
ment option [1, 5–8]. Several are commercially avail-
able and approved by the U.S. Food and Drug
Administration (FDA). Among the most popular are
the St. Jude Medical Biocor (St. Jude Medical, St. Paul,
MN) and the Carpentier-Edwards Perimount mitral
valve bioprosthesis (Edwards Lifesciences, Irvine, CA).
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With both of those valves, the published short- and
long-term hemodynamic and clinical data have sug-
gested good outcomes [7, 9–12].
In 2008, Edwards Lifesciences modified that initial Peri-
mount model to provide a lower profile and to enhance re-
moval of calcium-binding sites through its ThermaFix
process. This modified model is referred to as the
Carpentier-Edwards Perimount Magna mitral valve bio-
prosthesis, or the Magna valve for short. It protrudes less
into the left ventricular outflow tract (LVOT) than its pre-
decessor, so it is appealing for patients with small ventricles
undergoing multiple valve procedures or reoperations. It is
also predicted to have less structural valve deterioration,
thanks to the ThermaFix process.
The Magna valve, building on the proven durability of
the initial Perimount model, has now been implanted in
centers around the United States. Yet no publication, until
now, has verified its short- and intermediate-term safety
and efficacy. Herein, we report our 5-year outcomes with
the use of the Magna valve in 70 patients implanted be-
tween 2008 through 2011 at a single center (the Cleveland
Clinic)—including short-term in vivo echocardiographic
data, which can be used as a reference for outcomes ana-
lyses and for future valve modifications.
Methods
Study population
For our study, we queried the Cardiovascular Information
Registry (Cleveland Clinic), a prospective database ap-
proved for use in research by the Institutional Review
Board. Included in our study population were patients
who underwent mitral valve replacement with the Magna
valve from 2008 through 2011 (our 4-year study period)
(Fig. 1). Excluded were patients who underwent mitral
valve repairs or replacements with other types of valves.
In general the Cleveland Clinic prefers mitral valve
repair whenever possible. When replacement is needed,
we have primarily used either the St. Jude Medical
Biocor or the Carpentier-Edwards Perimount mitral
valve bioprosthesis; however, since 2008, our experience
with the Magna valve has been gradually accumulating.
After querying the Cardiovascular Information Registry,
we reviewed patients’ electronic medical records and
entered their clinical data into our own working database
for analysis. This database was approved for use by the
Cleveland Clinic’s Institutional Review Board, which waived
the need for consent from individual patients. Clinical data
included demographic variables, comorbidities, operative
details, postoperative outcomes, and intermediate-term
follow-up results. To confirm preoperative atrial fibrillation,
we reviewed the preoperative electrocardiogram. Coronary
artery disease was defined as ≥50 % obstruction of a coron-
ary vessel that may or may not have been amenable to by-
pass. Emergency operations were performed within 24 h
after the clinical diagnosis. Carotid artery disease was de-
fined as ≥50 % obstruction, per carotid artery duplex scan
findings. Pulmonary hypertension was defined as right ven-
tricular systolic pressure (RVSP) ≥40 mmHg, per echocardi-
ography findings.
Endpoints
Endpoints were postoperative hemodynamic measure-
ments, in-hospital morbidity and mortality, valve-related
events, resource utilization, clinically significant struc-
tural valve degeneration and intermediate-term survival
rates. To define in-hospital morbidity (perioperative
myocardial infarction, respiratory failure, sepsis, renal
failure, and neurologic complications), we used the Soci-
ety of Thoracic Surgeons national Adult Cardiac Surgery
database. For surviving patients, we used hospital length
of stay as a surrogate marker for resource utilization.
Clinically relevant structural valve degeneration was de-
fined as the need for reoperation or severe regurgitation
or stenosis preceding death.
Hemodynamic measurements
For the echocardiography findings, we retrieved the last
available transthoracic study from our server for each
patient; for all quantifications, we used Syngo software
(Siemens AG, Munich, Germany), with interpretations
made by two experienced echocardiologists (A.S and
W.S.). For the 2D echocardiography analysis of LVOT
diameter, left ventricular ejection fraction (EF), and
stroke volume (SV), we used the biplane method of disks
(modified Simpson’s rule). We also recorded RVSP, peak
and mean transmitral gradients (mmHg), left atrial (LA)
Fig. 1 a. Original Carpentier-Edwards Perimount design. b. Magna valve based on the original design but now with a lower profile and Therma
fix processing
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size, left ventricular internal diameter (LVID), and effect-
ive orifice area (EOA).
To calculate the LVOT systolic velocity time integral
(VTI), we used the mean of three waveforms acquired
by LVOT pulse-wave Doppler; then, to calculate SV, we
multiplied LVOT diameter by LVOT VTI. If systolic
LVOT VTI was not available, we obtained SV by using
the biplane method of disks (modified Simpson’s rule).
To calculate the peak transmitral gradient, we ob-
tained measurements from mitral diastolic continuous-
wave Doppler assessment and then used the simplified
Bernoulli equation. To calculate the mean transmitral
gradients, we obtained measurements from the diastolic
waveform VTI. For both the peak and mean measure-
ments, we used the mean of three waveforms.
To calculate the mitral valve area (MVA), we used the
pressure half-time (t1/2) method (MVA = 220/t1/2). To
calculate the mitral EOA, we divided SV by the mitral
diastolic VTI. To calculate the EOA index, we divided
the EOA by body surface area.
To assess the presence and degree of mitral regurgitation,
we used the four-chamber view per color flow Doppler
imaging, according to the semiquantitative approach rec-
ommended by the American Society of Echocardiography.
In six of the 70 patients, postoperative transthoracic 2D
echocardiograms were not available for analysis.
Data analysis
Continuous demographic variables are expressed as the
mean ± the standard error of the mean (SE); categorical
values are expressed as the n (percentage). To compare
pre- and postoperative echocardiography findings, we
used the paired Student t test. To assess intermediate-
term survival (in months) after Magna valve implant-
ation, we used the Kaplan-Meier method, with censoring
(N = 70, with n = 16 deaths, 54 censored). To assess free-
dom from structural valve degeneration we used the
Kaplan-Meier method (N = 70, with n = 2 events, 68 cen-
sored). To analyze the relationship between dichotom-
ous variables and survival, we used the 2-tailed Fisher
exact test.
Results
Preoperative demographic and clinical characteristics are
reported in Table 1. The mean age was 68 years (range, 29
to 88). Of the 70 patients, 30 (43 %) had New York Heart
Association (NYHA) class III or IV disease. The Magna
valve implantation was considered an emergency operation
in 3 (4.3 %) of the patients; 9 (12.8 %) were in cardiogenic
shock preoperatively. Additionally, 36 (51.4 %) of the
patients had moderately severe, or worse, mitral regurgita-
tion; 21 (30 %), severe mitral stenosis. In terms of previous
surgery, 30 (42.8 %) of the patients had undergone at least
1 previous cardiac operation; 19 (27.1 %), a previous mitral
valve repair or replacement.
Operative factors and findings are summarized in
Table 2. Of the 70 patients, 69 (98.6 %) underwent a full
sternotomy. The most common approach to Magna
valve implantation was transeptal with subvalvular leaflet
preservation. The most common Magna valve size was
29 mm, followed by 25 mm. Mitral annular calcification
was the most common operative finding, followed by de-
generative disease. Most patients had at least 1 add-
itional procedure performed at the time of the Magna
valve implantation.
Thirty eight patients had at least some MAC docu-
mented in the operative note. Moderate to severe MAC
was noted in 29 of these cases (57 %). MAC involved the
anterior annulus in 22 cases (57 %) and the posterior an-
nulus in 36 cases (94 %). In 17 cases (44 %) the MAC
was left undisturbed.
Twelve cases (31 %) required at least some debridement
and nine cases (23 %) required extensive debridement.
Annular reconstruction with a patch was used to avoid
AV rupture if adipose tissue was visible on the ventricular
side of the annulus after debridement. Three cases (8 %)
used a bovine pericardial patch and 1 case (3 %) used a felt
patch. Only one case required an additional bypass run
for mild-moderate perivalvular regurgitation to reinforce a
separation along the anterior rim. The rest had either no
or trivial MR at the conclusion of the replacement.
Postoperative complications are detailed in Table 3.
We noted five in-hospital deaths, for a mortality rate of
7.4 % in the immediate postoperative period. For the
remaining 65 survivors, the mean hospital length of stay
was 12 days (range, 4 to 42). Two patients (2.9 %) suf-
fered a stroke within 30 days. The most common
rhythm disturbance was atrial fibrillation (71 %). In all, 6
(8.5 %) of the patients developed renal failure requiring
dialysis; 3 (4.2 %) suffered an in-hospital cardiac arrest.
The average clinical follow-up was 16 months (range,
0–62 months). The 2- and 5-year survival rates were 84
and 40 % respectively. The median survival was 4.7 years
(Fig. 2). Several dichotomous perioperative factors were
associated with nonsurvival, including preoperative atrial
fibrillation, ischemic mitral regurgitation, use of an
intraaortic balloon pump (IABP), cardiogenic shock,
cardiac arrest, and renal failure (Table 4). Interestingly,
RVSP ≥40 mmHg was associated with a higher survival
rate on univariate analysis (P = 0.02) suggesting, at mini-
mum, that no penalty was incurred for Magna valve
implantation in patients with moderate pulmonary
hypertension.
Pre- and postoperative echocardiography findings are
compared in Table 5. The mean follow-up time for post-
operative echocardiography was 5 months (range, 0.3 to
50 months). Per their final echocardiogram during our
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study period, 98 % of surviving patients had trivial or no
mitral regurgitation, one patient had mild mitral regurgi-
tation and one patient had severe mitral regurgitation.
No short term valve related events such as vegetations,
dehiscence, degeneration, stenosis, or thrombosis were
documented on any of the postoperative echocardio-
grams. However, one patient had obstruction of the
LVOT by a strut requiring a reoperation at 2 years.
Two patients had evidence of severe structural valve
degeneration on follow-up (Fig. 3). In one, severe pros-
thetic MR was present at 2 years and the patient died
before a reoperation. In the other patient, severe mitral
calcification was noted during a redo AVR 6 months
after the initial Magna valve implantation. The postoper-
ative EF decreased by a mean of 2.5 % across matched
pairs, although the difference was not statistically signifi-
cant (Table 5). We observed a trend toward a reduction
in LA size and in LVID.
The peak transmitral gradient decreased as the
Magna valve size increased (Fig. 4). The same was true
for the mean transmitral gradient. However, we noted
Table 1 Patient characteristics (N = 70)a
Demographics
Age, years 68 ± 1.6
Gender
Men 36 (51 %)
Women 34 (49 %)
Preoperative clinical and laboratory values
BMI,b kg/m2 26.5 ± 0.7
Hematocrit, % 35.8 ± 0.7
Creatinine (mg/dl) 1.6 ± 0.2
Disease acuteness
NYHA functional class
I or II 40 (57 %)
III or IV 30 (43 %)
Emergency operation
Yes 3 (4.3 %)
No 67 (96 %)
IABP use
Yes 3 (4.3 %)
No 67 (96 %)
Cardiac comorbidities
Coronary artery disease 21 (30 %)
EF, % 55 ± 1.2
Moderately severe, or worse, MR 36 (51 %)
Severe MS 21 (30 %)
History of heart failure
Yes 22 (31 %)
No 48 (69 %)
Previous MI
Yes 10 (14 %)
No 60 (86 %)
Preoperative cardiogenic shock 9 (13 %)
Yes
No 61 (87 %)
History of peripheral artery disease
Yes 4 (5.7 %)
No 66 (94 %)
Previous cardiac operation
Yes 30 (43 %)
No 40 (57 %)
Previous mitral valve repair or replacement
Yes 19 (27 %)
No 51 (73 %)
Preoperative AF
Yes 19 (27 %)
No 51 (73 %)
Table 1 Patient characteristics (N = 70)a (Continued)
History of hypertension
Yes 53 (76 %)
No 17 (24 %)
Noncardiac comorbidities
Previous stroke
Yes 8 (11 %)
No 62 (89 %)
History of carotid artery diseaseb
Yes 26 (37 %)
No 43 (61 %)
History of smoking
Yes 29 (41 %)
No 41 (59 %)
History of COPD
Yes 11 (16 %)
No 59 (84 %)
History of DM
Yes 17 (24 %)
No 53 (76 %)
History of renal disease
Yes 20 (29 %)
No 50 (71 %)
BMI body mass index, NYHA New York Heart Association, IABP intraaortic
balloon pump, EF ejection fraction, AF atrial fibrillation, MI myocardial
infarction, COPD chronic obstructive pulmonary disease, DM diabetes mellitus,
MR mitral regurgitation, MS mitral stenosis
aContinuous variables expressed as mean ± standard error of the mean (SE);
categorical variables, as n (percentage)
bData available for only 69 patients
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no statistically significant differences in the mean gradi-
ent between the two most commonly employed valve
sizes (29 and 25 mm), suggesting that even a small
Magna valve was capable of yielding a low mean gradi-
ent. Although we noted a trend toward lower RVSP
values for each Magna valve size, the only statistically
significant decrease was with 31 mm (Fig. 5). The Ef-
fective Orifice Area Index (EOAI) did not vary signifi-
cantly between valve sizes except for the 31 mm valve
which had a statistically higher value than the 25 mm
valve (Fig. 6).
Discussion
Our 5-year study is the first to objectively evaluate the
hemodynamic and clinical outcomes with the Magna
valve, a modification of the earlier Carpentier-Edwards
Perimount mitral valve bioprosthesis. We found excellent
intermediate-term durability with this versatile design,
which is well suited for complex situations; even at the
lowest valve sizes, this new model provided patients with
excellent hemodynamics.
Most of the patients in our series had extensive co-
morbidities, a high NYHA class, severe valve disease,
and previous cardiac operations, many of which in-
volved the mitral valve. Thus, our patients were typical
of those undergoing mitral valve replacement in the
current era [1, 4, 13]. While the survival rate at 2 years
of 84 % was excellent, the survival rate of 40 % at
5 years was commensurate with this cohorts’ extent of
illness. For comparison, the St. Jude Medical Biocor
valve series from Rizzoli et al. noted a 5-year survival
rate of 54 % [12]. The 15 year experience with the ori-
ginal Perimount bioprosthesis showed a 5 year survival
of 76 %, although their cohort had fewer comorbidities
and less reoperations than observed in the current
study [7]. We also observed significant postoperative
morbidity, including renal failure, cardiogenic shock,
and respiratory failure. One patient suffered a death
due to AV groove disruption which was related to se-
vere MAC rather than the Magna valve itself. One re-
operation was required at 2 years due to LVOT
obstruction from a strut. These cases highlight the need
for caution even with this low-profile design. The free-
dom from structural valve degeneration of 90 % was ex-
cellent and compares favorably with that observed in
other series [7, 12]. One reoperation was due to struc-
tural valve degeneration at 6 months and one patient
died due to severe MR at 2 years without a reoperation.
We identified several factors associated with increased
mortality in our patients, including atrial fibrillation, cardio-
genic shock, IABP use, cardiac arrest, and ischemic mitral
regurgitation. Wang et al. also found significantly increased
mortality in patients with preoperative atrial fibrillation, but
they found improved survival with a concomitant Cox
Table 2 Operative factors and findings (N = 70)a
Operative factors
Indication
MR 49 (70 %)
MS 19 (27 %)
Endocarditis 10 (14.2 %)
Attempted repair
Yes 7 (10 %)
No 63 (90 %)
Minimally invasive Magna valve implantation
Yes 1 (1.4 %)
No (i.e., full sternotomy) 69 (99 %)
Technique for Magna valve implantation
Transseptal approach 49 (70 %)
Left atriotomy 21 (30 %)
Subvalvular leaflet preservation 56 (80 %)
Magna valve sizeb (mm) 28 ± 0.3
25 18 (26 %)
27 16 (23 %)
29 19 (27 %)
31 16 (23 %)
33 1 (1.4 %)
Findings
Rheumatic disease 12 (17 %)
Myxomatous disease 4 (5.7 %)
Ruptured chordae 5 (7.1 %)
Degenerative disease 28 (40 %)
Vegetations 10 (14 %)
MAC 38 (54 %)
Ischemic MR (posterior restriction) 3 (4.3 %)
Concomitant procedures
Any 58 (83 %)
CABG 6 (8.6 %)
AVR, TVR, ASD repair,
and/or myectomy
33 (47 %)
CABG + AVR, TVR, ASD repair,
and/or myectomy
11 (16 %)
AVR 24 (34 %)
Triple valve procedures 6 (8.6 %)
Antiarrhythmic procedure
(Cox maze procedure, PVI,
and/or LAAL)
7 (10 %)
mm millimeters, MR mitral regurgitation, MS mitral stenosis, MAC mitral
annular calcification, CABG coronary artery bypass grafting, AVR aortic valve
replacement, TVR tricuspid valve repair, ASD atrial septal defect, PVI pulmonary
vein isolation, LAAL left atrial appendage ligation
aContinuous variables expressed as mean ± standard error of the mean (SE);
categorical variables, as n (percentage)
bData available for only 68 patients
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maze and LA ligation [14]. In our series, despite the 27 %
incidence of preoperative atrial fibrillation, only 10 % of our
patients underwent an antiarrhythmic procedure—perhaps
a reflection of the length and complexity of the procedures,
along with the frailty of the tissues, which discouraged an-
cillary procedures that were not absolutely necessary in
these older patients.
Table 3 Postoperative course and complications (N = 70)a
Hospital LOS,b days 11.6 ± 0.8
Cardiogenic shockc 6 (8.6 %)
IABP use 2 (2.9 %)
Tracheostomy 4 (5.7 %)
Any renal failure 17 (24 %)
Renal failure requiring dialysis 6 (8.6 %)
Reoperation for bleed 4 (5.7 %)
AF 50 (71 %)
Heart block 19 (27 %)
Transient 16 (23 %)
Permanent pacer 3 (4.2 %)
Wound infection 1 (1.4 %)
Cardiac arrest 3 (4.3 %)
In-hospital death 5 (7.1 %)
Stroke 2 (2.9 %)
Valve-related complications
Thrombosis 0 (0 %)
Dehiscence 0 (0 %)
LVOTOd 1 (1.4 %)
Vegetations 0 (0 %)
AV groove disruption 1 (1.4 %)
AF atrial fibrillation, AV atrioventricular, IABP intraaortic balloon pump, LOS
length of stay, LVOTO left ventricular outflow tract obstruction
aContinuous variables expressed as mean ± standard error of the mean (SE);
categorical variables, as n (percentage)1
bData available for only 65 patients
cData available for only 69 patients
dRequired reoperation at 2 years
Fig. 2 Kaplan-Meier non-parametric estimate of all-cause mortality
based on the observed survival in patients with the Carpentier-
Edwards Magna valve in the mitral position with censoring (N = 70,
with n = 16 deaths, 54 censored). X-axis represents time after valve
implant, in months. aNumber at risk for each 10 month interval
beginning with n of 70
Table 4 Factors associated with increased mortality (N = 70)a
Survivors (n = 62) Nonsurvivors (n = 8) Pb
AF 14 (23 %) 5 (63 %) 0.02
Ischemic MR 1 (1.6 %) 3 (38 %) 0.03
IABP use 0 (0 %) 2 (25 %) 0.01
Cardiogenic shock 2 (3.2 %) 4 (50 %) 0.001
Cardiac arrest 1 (1.6 %) 2 (25 %) 0.03
Any renal failure 15 (24 %) 6 (75 %) 0.007
AF atrial fibrillation IABP intraaortic balloon pump, MR mitral regurgitation
a Continuous variables expressed as mean ± standard error of the mean (SE);
categorical variables, as n (percentage)
b Relationship between dichotomous variables and survival analyzed with 2-
tailed Fisher exact tests
Table 5 Pre- and postoperative echocardiography findings
(N = 70)a
Left ventricular EFb
Preoperative, % 54.8 % ± 1.25 %
Postoperative, % 52.3 % ± 1.67 %
Difference, % −2.50 % ± 1.57 %
P 0.1160
RVSPc
Preoperative, mmHg 50.1 ± 3.23
Postoperative, mmHg 39.8 ± 2.18
Matched-pair difference, mmHg −10.3 ± 3.23
P 0.0025
LA sized
Preoperative, cm2 5.557 ± 0.560
Postoperative, cm2 4.641 ± 0.113
Matched-pair difference, cm2 −0.915 ± 0.558
P 0.1158
LVIDe
Preoperative, cm 4.705 ± 0.883
Postoperative, cm 4.598 ± 0.863
Matched-pair difference, cm −0.107 ± 0.098
P 0.116
cm centimeters, EF ejection fraction, LA left atrial, LVID left ventricular internal
diameter, mmHg millimeters of mercury, RVSP right ventricular
systolic pressure
aContinuous variables expressed as mean ± standard error of the mean (SE)
bBoth pre- and postoperative data available for only 64 patients
cBoth pre- and postoperative data available for only 49 patients
dBoth pre- and postoperative data available for only 46 patients
eBoth pre- and postoperative data available for only 58 patients
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De Bonis et al. recently showed that ischemic mitral
regurgitation in sicker patients was associated with
lower survival when the mitral valve was replaced ra-
ther than repaired [15]. Conversely, Gillinov et al.
found no difference in survival between repair and re-
placement in patients with a higher NYHA class and
complex regurgitant jets [4]. This is consistent with
the randomized controlled prospective trial of Acker
and colleagues that showed no survival benefit for re-
pair over replacement and greater durability with
valve replacement [16]. We believe it is reasonable to
use the Magna valve for ischemic mitral regurgitation,
although repair should be considered in appropriate
candidates.
What are the advantages of a lower-profile bioprosthesis?
Patients receiving a mitral prosthesis have a natural reduc-
tion in the LVOT [17]. In addition, the struts of a bulky bio-
prosthetic can protrude into the LVOT, causing a clinically
significant increase in gradients [18]. A smaller, lower-
profile valve reduces such concerns. Reoperative or
multiple-valve procedures in patients with mitral annular
calcification or degenerative disease pose additional restric-
tions on the prosthesis size. The exposure in such proce-
dures is challenging; the mitral annulus and left ventricular
cavities are often restricted. Most patients in our series
underwent a full sternotomy, with transseptal mitral expos-
ure and with implantation of a small Magna valve (25 to
29 mm). In addition, in patients with ischemic mitral
Fig. 3 Kaplan-Meier non-parametric estimate of freedom from structural valve degeneration, as defined by a need for reoperation due to valve
dysfunction preceding death, in patients with the Carpentier-Edwards Magna valve in the mitral position (N = 70, with n = 2 events, 68 censored).
X-axis represents time after valve implant, in months. aNumber at risk for each 10 month interval beginning with n of 70
Fig. 4 Postoperative peak (gray circles) and mean (dark boxes)
transmitral gradients (in millimeters of mercury) per
echocardiography by Magna valve size (in millimeters). Asterisks =
means that are significantly different (P < 0.05)
Fig. 5 Preoperative (gray circles) and postoperative (dark boxes) right
ventricular systolic pressure (RVSP) (in millimeters of mercury) per
echocardiography by Magna valve size (in millimeters). Asterisks =
pre- and postoperative matched pairs that are significantly
different (P < 0.05)
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regurgitation, the Magna valve’s low-profile design is more
likely to allow preservation of the subvalvular apparatus
which may be associated with improved survival [19, 20].
In our series, 80 % of patients had preservation of some
portion of the subvalvular apparatus, with no reported out-
flow obstruction.
The mean gradients achieved with the Magna valve in
our series compared favorably with those reported in
previous publications on other mitral bioprostheses
[10–12]. Our lowest gradients were achieved with the
27 and 31-mm Magna valves, although the gradients
achieved with the 25-mm Magna valve were only
slightly higher. Thus, the 25-mm valve size is a reason-
able option for patients with a constrained annulus or
small ventricle, especially when left ventricular outflow
tract obstruction (LVOTO) is a concern. While the low
profile design may reduce the incidence of LVOTO,
care must still be taken to keep the struts out of the
way of the LVOT as one case in this series did demon-
strate LVOTO resulting in redo-replacement.
The valve size of 25 was the second most common
size used in this series which suggests small working
annuluses. This could be explained by variations in pa-
tient anatomy or surgical technique, high rate of MAC
with limited debridement, and/or the presence of reo-
perations. We tend to use either inverting (ventricular to
atrial) or everting (atrial to ventricular) suture tech-
niques depending on anatomy and ease of placement.
We favor inverting sutures in the setting of MAC which
places the sewing ring on the atrial side of the mitral an-
nulus. If everting sutures are used then the valve may sit
slightly intra-annular. We will infrequently construct a
neo-inner annulus as described by Di Stefano and col-
leagues to avoid debridement in the setting of severe
MAC [21]. The presence of favorable mean gradients
suggests that the range of Magna sizes can accommo-
date the operator’s preference and/or patient’s anatomy.
The favorable hemodynamic profile of the Magna valve
is further supported by the significant reduction we
observed in RVSP. It is anticipated that a persistent reduc-
tion in RVSP could correlate with improved long-term
survival, but we did not have a large enough sample size
or long enough follow-up to definitively show any correl-
ation [22]. The suggestion that even smaller Magna valve
sizes produce favorable hemodynamics is supported by
the fact that we saw no appreciable difference in EOA
index across valve sizes, except for the 31-mm valve.
Our study supports the use of the Magna valve as a re-
placement option, but we acknowledge several important
limitations. First, echocardiographic follow-up was not as
standardized as it is for repairs and not all patients had
echos at their longest follow-up interval. Echocardiog-
raphy was generally obtained if a clinical indication was
met. Thus, our review of structural valve degeneration
was limited to the causes of death, reoperation and the last
available echo prior to these events. The Magna valve de-
sign is based on the previous Perimount model, which is
associated with 14 years’ worth of data showing freedom
from explantation and from structural valve deterioration,
so we are confident that the newer model will do at least
as well. Additionally, the prospective evaluation of the
echocardiograms by two experienced cardiologists was
crucial as it standardized the valve’s performance mea-
sures. But it was limited to a mean follow-up of 5 months
with a broad range of intervals. We elected to evaluate the
last echos to avoid an unfair advantage from early postop-
erative performance. We noted a high interobserver vari-
ability for the calculation of the EOA index in our series,
making it difficult to reach conclusions about the actual
value for any given Magna size. However, we were able to
make statistical comparisons for changes in the EOA
index across valve sizes. Our study was underpowered for
a multivariate analysis, although trends were established
by univariate measures.
The peak gradient for the 25, 29 and 31 mm valves
gradually decreased as expected. However, the peak was
higher for the 29 mm valve than the 27 mm valve. Simi-
larly, the 25, 27 and 31 mm mean gradients gradually
decreased as expected. But the mean for the 29 and
25 mm valves were not statistically different. Peak and
mean gradients can be affected by various transient factors
such as cardiac output, heart rate, and volume status. In
addition, the patient population was heterogeneous and
we did not have an equal distribution of patients through-
out the various valve sizes. Thus, we can conclude that
the peaks and means decreased in our series with larger
valve sizes as expected but we cannot give definitive esti-
mates of these relative gradients that would translate to a
broader population.
Conclusions
In conclusion, this is the first published report on outcomes
after implantation of the Magna valve. Modifications are
Fig. 6 Effective Orifice Area Index (EOAI) across various valve sizes.
The asterisk denotes a significant difference between the 31 and
25 mm EOAI
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regularly made to valves; it is important that at least short-
term results are made available. In our 5-year study, we
found excellent freedom from structural valve degeneration,
excellent short term survival, good hemodynamics at even
the lowest valve sizes, substantial echocardiographic im-
provement, and minimal valve-related events. The Magna
valve’s low-profile design and ThermaFix process make it
ideal for patients who have small ventricles, extensive co-
morbidities, or complex valve disease, as well as for those
who need reoperations and concomitant cardiac proce-
dures, including valve replacement.
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